Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis

Chih-Wei Luan; Liang-Tseng Kuo; Yun-Ting Wang; Chun-Ta Liao; Chung-Jan Kang; Yi-Chan Lee; Kuan-Yin Chen; Chia-Hsuan Lai; Yuan-Hsiung Tsai; Ethan I Huang; Ming-Shao Tsai; Cheng-Ming Hsu; Geng-He Chang; Yao-Te Tsai

doi:10.1002/hed.27397

Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis

Head Neck. 2023 Jul;45(7):1856-1867. doi: 10.1002/hed.27397. Epub 2023 May 10.

Authors

Chih-Wei Luan^{1

2

3}, Liang-Tseng Kuo^{2

4}, Yun-Ting Wang⁵, Chun-Ta Liao^{2

6}, Chung-Jan Kang^{2

6}, Yi-Chan Lee^{2

7}, Kuan-Yin Chen⁸, Chia-Hsuan Lai^{2

9}, Yuan-Hsiung Tsai^{2

10}, Ethan I Huang^{2

5}, Ming-Shao Tsai^{2

5}, Cheng-Ming Hsu^{2

5}, Geng-He Chang^{2

5}, Yao-Te Tsai^{2

5}

Affiliations

¹ Department of Otorhinolaryngology - Head and Neck Surgery, LO-Sheng Hospital Ministry of Health and Welfare-Home, Taoyuan, Taiwan.
² College of Medicine, Chang Gung University, Taoyuan, Taiwan.
³ Lunghwa University of Science and Technology, Taoyuan, Taiwan.
⁴ Division of Sports Medicine, Department of Orthopedic Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan.
⁵ Department of Otorhinolaryngology - Head and Neck Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan.
⁶ Department of Otorhinolaryngology - Head and Neck Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
⁷ Department of Otorhinolaryngology - Head and Neck Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan.
⁸ School of Dentistry, National Yang Ming University, Hsinchu, Taiwan.
⁹ Department of Radiation Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
¹⁰ Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chiayi, Taiwan.

PMID: 37161915
DOI: 10.1002/hed.27397

Abstract

Whether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random-effects meta-analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression-free survival (HR = 2.39, 95% CI 1.69-3.38), overall survival (HR = 2.40, 95% CI 1.94-2.98), disease-specific survival (HR = 2.57, 95% CI 1.71-3.88), and disease-free survival (HR = 2.67, 95% CI 1.51-4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.

Keywords: head and neck cancer; meta-analysis; modified Glasgow prognostic score; squamous cell carcinoma; survival outcome.

Publication types

Meta-Analysis
Systematic Review
Review
Research Support, Non-U.S. Gov't

MeSH terms

Disease-Free Survival
Head and Neck Neoplasms* / therapy
Humans
Prognosis
Proportional Hazards Models
Squamous Cell Carcinoma of Head and Neck